Invivyd Inc (IVVD) Actualités

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Invivyd Elects Two New Independent Members to its Board of Directors

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Form 144 - Report of proposed sale of securities

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents...

Form 8-K - Current report

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior...

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial...

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224...

Invivyd Announces CEO Transition

WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...